344 related articles for article (PubMed ID: 1649265)
1. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG
J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265
[TBL] [Abstract][Full Text] [Related]
2. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
[TBL] [Abstract][Full Text] [Related]
4. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
6. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
7. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Roth BJ; Johnson DH; Einhorn LH; Schacter LP; Cherng NC; Cohen HJ; Crawford J; Randolph JA; Goodlow JL; Broun GO
J Clin Oncol; 1992 Feb; 10(2):282-91. PubMed ID: 1310103
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
Ettinger DS; Finkelstein DM; Abeloff MD; Ruckdeschel JC; Aisner SC; Eggleston JC
J Clin Oncol; 1990 Feb; 8(2):230-40. PubMed ID: 2153765
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
11. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.
Murray N; Shah A; Osoba D; Page R; Karsai H; Grafton C; Goddard K; Fairey R; Voss N
J Clin Oncol; 1991 Sep; 9(9):1632-8. PubMed ID: 1651995
[TBL] [Abstract][Full Text] [Related]
12. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
[TBL] [Abstract][Full Text] [Related]
13. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer.
Erkişi M; Unsal M; Tunali C; Burgut R; Doran F
J Chemother; 1993 Feb; 5(1):56-9. PubMed ID: 8384659
[TBL] [Abstract][Full Text] [Related]
14. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
Littlewood TJ; Smith AP; Anderson G; Chappell AG; James KW
Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
[TBL] [Abstract][Full Text] [Related]
17. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
Havemann K; Wolf M; Holle R; Gropp C; Drings P; Manke HG; Hans K; Schroeder M; Heim M; Victor N
Cancer; 1987 Mar; 59(6):1072-82. PubMed ID: 3028596
[TBL] [Abstract][Full Text] [Related]
18. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
[TBL] [Abstract][Full Text] [Related]
20. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
